Early Clinical Trial Concept for Boron Neutron Capture Therapy - A Critical Assessment of the EORTC Trial 11001
BNCT causes selective damage to tumor cells by neutron capture reactions releasing high LET-particles where 10B-atoms are present. Neither the 10B-compound nor thermal neutrons alone have any therapeutic effect. Therefore, the development of BNCT to a treatment modality needs strategies, which differ from the standard phase I¿III clinical trials. An innovative trial design was developed including translational research and a phase I aspect. The trial investigates as surrogate endpoint BSH and BPA uptake in different tumor entities.
WITTIG Andrea;
COLLETTE Laurence;
MOSS Raymond;
SAUERWEIN Wolfgang;
2009-12-17
PERGAMON-ELSEVIER SCIENCE LTD
JRC56052
0969-8043,
www.elsevier.com/locate/apradiso,
https://publications.jrc.ec.europa.eu/repository/handle/JRC56052,
10.1016/j.apridiso.2009.03.012,
Additional supporting files
| File name | Description | File type | |
|---|
